HC Wainwright Lowers Curis (NASDAQ:CRIS) Price Target to $16.00

Curis (NASDAQ:CRIS) had its target price decreased by equities researchers at HC Wainwright from $20.00 to $16.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock.

Separately, StockNews.com began coverage on shares of Curis in a research report on Saturday. They set a “hold” rating on the stock.

Curis Trading Down 30.5 %

NASDAQ:CRIS opened at $1.46 on Monday. Curis has a 1-year low of $1.40 and a 1-year high of $17.49. The firm has a market capitalization of $12.36 million, a price-to-earnings ratio of -0.19 and a beta of 3.49. The business’s 50-day moving average price is $2.97 and its two-hundred day moving average price is $3.83.

Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($1.25) EPS for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.11. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. The company had revenue of $2.70 million during the quarter, compared to analysts’ expectations of $2.04 million. Sell-side analysts predict that Curis will post -7.12 earnings per share for the current year.

Hedge Funds Weigh In On Curis

Several institutional investors have recently modified their holdings of the business. CM Management LLC raised its holdings in Curis by 83.3% during the 4th quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after buying an additional 100,000 shares during the period. Focused Wealth Management Inc raised its holdings in shares of Curis by 9.5% during the fourth quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after acquiring an additional 5,138 shares during the period. Millennium Management LLC lifted its position in Curis by 92.6% in the 4th quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 12,287 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Curis in the 4th quarter worth $35,000. Finally, Alyeska Investment Group L.P. bought a new position in Curis during the 4th quarter worth about $607,000. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.